[EN] INHIBITORS OF JMJD2C AS ANTICANCER AGENTS<br/>[FR] INHIBITEURS DE JMJD2C UTILISÉS EN TANT QU'AGENTS ANTICANCÉREUX
申请人:DAVID GLADSTONE INST
公开号:WO2015167874A1
公开(公告)日:2015-11-05
The present disclosure provides compounds, pharmaceutical compositions and related methods for the treatment of cancer, e.g., castration-resistant prostate cancer (CRPC). Specifically, the present disclosure provides a series of 8-hydroxyquinoline derivatives which show cytotoxic effects on androgen-independent prostate cancer cells.
The present disclosure provides compounds, pharmaceutical compositions and related methods for the treatment of cancer, e.g., castration-resistant prostate cancer (CRPC). Specifically, the present disclosure provides a series of 8-hydroxyquinoline derivatives which show cytotoxic effects on androgen-independent prostate cancer cells.
Discovery of Novel 8-Hydroxyquinoline Derivatives with Potent <i>In Vitro</i> and <i>In Vivo</i> Antifungal Activity
yet current antifungals are inadequate at treating many of these, highlighting the importance of novel drug discovery. Here, we report hit compound L14, a novel 8-hydroxyquinoline derivative with potent and broad-spectrum antifungal activity. In vitro experiments exhibited that L14 had better activity and lower cytotoxicity than that of clioquinol and showed synergy in combination with fluconazole